Mediterranean Diet, Humanin, and a New Cardiac Hypothesis

The Mediterranean diet already has a strong record in cardiovascular health. A small 2026 study offers an intriguing explanation for part of that benefit: people with higher adherence had higher blood levels of two mitochondria-derived microproteins, Humanin and SHMOOSE. Humanin also tracked with lower activity of Nox2, an enzyme that contributes to oxidative stress.

That is an interesting biological lead, not a reason to start treating a Humanin blood test like a dashboard light. The study was cross-sectional, included 49 older adults with atrial fibrillation at one Italian center, and could not show that diet raised either peptide or that either peptide prevented cardiovascular events.

A mitochondrial clue, not a new reason to eat well

Mitochondria do more than turn food into usable energy. Their DNA also encodes small signaling molecules called mitochondria-derived peptides. Humanin is a 24-amino-acid peptide encoded within the mitochondrial MT-RNR2 region. Researchers have detected it in human vascular walls, and earlier work has linked it with protection against oxidized LDL and preservation of coronary endothelial function. Low circulating Humanin has also been associated with greater coronary artery disease risk in cross-sectional research.

SHMOOSE is another mitochondria-derived peptide, identified more recently. Its emerging research has focused mainly on neuroprotection; human cardiovascular evidence remains scarce. Both molecules can be measured in plasma, but a measurable biomarker is not automatically a useful clinical target.

The new paper, Vicinanza et al. 2026, proposes that Mediterranean-style eating may influence these mitochondrial signals and that Humanin may help restrain Nox2-mediated oxidative stress. Nox2 produces superoxide, a reactive molecule involved in vascular oxidative stress. Reducing excessive Nox2 activity is a plausible route to healthier endothelial function. The missing piece is proof that Humanin controls Nox2 in human cardiovascular tissue after a dietary intervention.

What the pilot study actually found

Vicinanza and colleagues analyzed 49 patients with non-valvular atrial fibrillation at the Atherothrombosis Center of Sapienza University of Rome. Participants had a mean age of 78.4 years, and 57% were female. The investigators used a nine-item Mediterranean diet score, then compared people with low-to-medium adherence, scores of 0 to 6, with those reporting high adherence, scores of 7 to 9. Each group contained roughly 24 or 25 people.

People in the high-adherence group had significantly higher circulating Humanin and SHMOOSE concentrations than those in the low-to-medium group. Humanin concentrations also correlated inversely with sNox2-dp, a circulating marker of Nox2 activation. In other words, within this small clinical sample, higher Humanin tended to accompany lower measured Nox2-related oxidative stress.

The result does not establish a sequence of events. A Mediterranean diet could raise Humanin, but higher Humanin could also correlate with some other feature of healthier participants. Physical activity, metabolic health, medication use, socioeconomic conditions, genetic background, and disease severity could affect both dietary patterns and mitochondrial signals. The study did not randomly assign diets, measure cardiovascular events, or follow participants over time. It measured associations at one point.

The study provides a plausible hypothesis: Mediterranean diet adherence may be associated with higher circulating Humanin and SHMOOSE, while Humanin may be associated with lower Nox2 activity. It does not prove that any one of those links causes the next.

Why the Nox2 link deserves attention

Two 2026 studies from the same Italian research group point in the same direction for the diet-and-oxidative-stress portion of the hypothesis. Neither measured Humanin or SHMOOSE, so neither validates the full proposed pathway. They do, however, add context for Nox2.

In patients with autosomal dominant polycystic kidney disease, Salomone et al. found that higher Mediterranean diet adherence was associated with lower sNox2-dp and lower hydrogen peroxide concentrations. In a separate cross-sectional study of chronic kidney disease patients with hypertensive nephropathy, the same group reported that Mediterranean diet adherence was associated with lower Nox2-mediated oxidative stress and better endothelial dysfunction markers.

These are convergent findings across distinct chronic disease populations, but they share important constraints: cross-sectional design, the same research group, and the same sNox2-dp ELISA platform. Replication in another laboratory and, more importantly, randomized dietary research would make the result much more persuasive. For now, the evidence supports an association between Mediterranean diet adherence and lower Nox2-related oxidative-stress markers in these clinical populations. It does not show that diet-induced Humanin changes caused those marker differences.

Blood Humanin is influenced by more than diet

Humanin has enough biological signal to make the hypothesis worth studying, but that same signal creates a major interpretation problem. Circulating mitochondria-derived peptides vary across human groups and disease states. Ramirez-Torres et al. 2022 found racial differences in circulating Humanin, SHLP2, and MOTS-c among male cohorts studied in a prostate-cancer context. That supports the feasibility of measuring these peptides in plasma, while showing that biology and demographics can influence concentrations.

Disease burden can matter even more. Amado et al. 2023 documented altered circulating mitochondrial signals at hospital admission for COPD exacerbation. Rodríguez-Espárragon et al. 2025 also examined measurable Humanin and MOTS-c expression in Alzheimer's disease. Research in prostate disease likewise identifies Humanin as a clinically measurable biomarker.

Those studies do not contradict the atrial-fibrillation finding. They show why it needs careful replication. In a cohort of older adults with cardiovascular disease and likely multiple medications, plasma Humanin and SHMOOSE may reflect illness, inflammation, or treatment as much as diet. No validated healthy reference range tells a person what an "optimal" Humanin concentration would be.

The Mediterranean diet does not need this mechanism to earn its reputation

The dietary pattern has outcome evidence that stands apart from this microprotein theory. A systematic review and dose-response meta-analysis of prospective cohorts, including 244,678 adults for overweight or obesity risk, linked greater Mediterranean diet adherence with less weight gain and lower risk of overweight or obesity over five years. Read the details in Lotfi et al. 2022.

Evidence also extends beyond cardiology. A 2024 meta-analysis of five randomized trials and 18 cohort studies involving 107,355 pregnant participants found that, in the randomized trials, a maternal Mediterranean diet was associated with lower gestational diabetes incidence, with an odds ratio of 0.56 and a 95% confidence interval of 0.34 to 0.93, and lower small-for-gestational-age risk, odds ratio 0.55, 95% confidence interval 0.35 to 0.88. Those findings appear in Xu et al. 2024.

Randomized trials have also reported benefits in specific clinical settings: a modified Mediterranean diet improved dietary inflammatory-index scores, fatigue, and disability measures versus a traditional Iranian diet in people with relapsing-remitting multiple sclerosis, while a 12-week trial evaluated the diet for depressive symptoms in young men with clinical depression. See Bohlouli et al. 2022 and Bayes et al. 2022. These studies do not test Humanin, SHMOOSE, or Nox2. Their value here is simpler: Mediterranean-style eating has evidence worth acting on even while its cellular details remain unsettled.

What to do with this finding

Follow a Mediterranean dietary pattern for its established body of outcome evidence, not to chase a speculative Humanin increase. The 2026 pilot study makes a coherent case for further work: larger prospective cohorts, objective dietary biomarkers, repeated peptide measurements, independent laboratories, and randomized interventions that test whether dietary change alters Humanin, SHMOOSE, Nox2 activity, endothelial function, and eventually cardiovascular outcomes.

Until those studies arrive, Humanin and SHMOOSE are research markers, not biohacking targets. The study offers a possible cellular explanation for an established dietary pattern. It does not yet offer a new protocol.